FDA licenses Ezplaz as the first freeze-dried plasma product for US use

The room-temperature-stable product provides an alternative for adults who require plasma when conventional plasma products are unavailable, including in emergency, remote and austere settings.

The US Food and Drug Administration has licensed Ezplaz Freeze Dried Plasma for transfusion in adults who require plasma when other plasma products are not available, making it the first freeze-dried plasma product licensed in the United States.

Its room-temperature storage, rapid reconstitution and transport-friendly packaging may support plasma access in settings where frozen products cannot be stored or prepared readily.

Field	Content
Alert Type	Drug Approval
Drug Name	Ezplaz Freeze Dried Plasma
Indication	Transfusion in adult patients when plasma is required and other plasma products are not available, including bleeding patients, patients requiring massive transfusion and certain patients receiving warfarin who are bleeding.
Therapy Area(s)	Transfusion Medicine; Emergency and Critical Care
Geography	US (FDA)
What Happened	On 29 July 2026, the FDA granted a biologics licence to Vascular Solutions, LLC, a Teleflex subsidiary, for Ezplaz Freeze Dried Plasma. The product is the first freeze-dried plasma licensed in the United States and is approved for transfusion in adults who require plasma when other plasma products are unavailable. Ezplaz is derived from a single unit of fresh frozen plasma and is available as Group AB and Group A with low-titre anti-B plasma. (U.S. Food and Drug Administration)
Why It Matters	Conventional plasma must be stored frozen and thawed before use, which can limit availability in combat zones, disaster response, rural areas and other settings without conventional blood-bank infrastructure. Ezplaz can be stored at room temperature, withstand temperature fluctuations and be reconstituted rapidly, providing clinicians with a licensed plasma option when standard products are unavailable. (U.S. Food and Drug Administration)
Supporting Context	Each kit contains one unit of freeze-dried plasma, sterile water for injection, a fluid-transfer set and a blood-transfusion set. The product is packaged in a plastic bag rather than a glass bottle, reducing breakage risk during handling and transport; its safety profile is consistent with other plasma products, although the established risks associated with plasma transfusion remain. (U.S. Food and Drug Administration)
Key Takeaway	Ezplaz extends access to licensed plasma transfusion for adults in settings where frozen plasma cannot be made available promptly.
What to Watch	Commercial availability, procurement by military and emergency-response organisations, and adoption by rural or remote healthcare services will determine how widely the product changes access to plasma outside conventional hospital settings.
Primary Source	https://www.fda.gov/news-events/press-announcements/fda-licenses-first-ever-freeze-dried-plasma-product-us
Relevant Date	29 July 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com